Protagonist Therapeutics, Inc PTGX
Analyst Ratings
- Consensus
- Buy — 13 Buy · 0 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $134.08 (-13.6% downside)
Key Stats
- Today's Range
- $149.17 – $155.53
- 50-Day Range
- $96.14 – $155.53
- 52-Week Range
- $50.48 – $155.53
- Volume
- 426K shs
- Average Volume
- 627K shs
- Market Cap
- $9.84 billion
- P/E Ratio
- 150.58
- Dividend Yield
- —
Valuation
- P/E Ratio
- 150.58
- Price / Book
- 11.69
- Price / Sales
- 34.88
Short Interest
- Short Interest
- 0.63%
- Days to Cover
- 3.89
Financials (TTM)
- Revenue
- $281.99 million
- Net Income
- $82.91 million
- Net Margin
- 29.40%
- Return on Equity
- 9.85%
- Debt-to-Equity
- —
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Related Stocks
Compare head-to-head: PTGX vs LLY·PTGX vs JNJ·PTGX vs ABBV·PTGX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.